...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children.
【24h】

FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children.

机译：在类固醇治疗的哮喘儿童中，FCER2 T2206C变体与慢性症状和病情加重有关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The T2206C FCER2 variant was found previously to be associated with IgE levels, exacerbation rates and decreased FCER2 expression in children on inhaled corticosteroids (ICS) participating in a clinical trial. This finding has not been replicated. We sought to replicate the association between the FCER2 gene and exacerbations in children with asthma. In addition, we tested the hypothesis that the T2206C variant may be associated with other markers of steroid resistance such as asthma symptom scores and asthma medication use. METHODS: The influence of the T2206C variant on asthma exacerbations (emergency department visits or hospitalization), symptoms scores and medication use was explored using data from two populations of asthmatic children using ICS: Pharmacogenetics of Asthma medication in Children: Medication with ANti-inflammatory effects study (n = 386) and BREATHE study (n = 939). RESULTS: The T2206C variant was associated with increased risk of asthma-related hospital visits in both cohorts (OR: 1.91, 95% CI: 1.08-3.40), and meta-analysis with previously published results was highly significant (OR: 2.38, 95% CI: 1.47-3.85, P = 0.0004). The FCER2 variant was also associated with increased risk of uncontrolled asthma measured by Asthma Control Questionnaire (OR: 2.64, 95% CI: 1.00-6.98) and was associated with increased daily steroid dose (OR: 2.46, 95% CI: 1.38-4.39). CONCLUSION: The association between the FCER2 T2206C variant and asthma-related hospitalizations in steroid-treated asthma appears robust and may also be associated with other indicators of lack of ICS efficacy such as asthma symptoms and a requirement for higher daily doses of ICS. Our results suggest that the FCER2 T2206C variant might be a useful pharmacogenetic predictor of steroid refractory patients.
机译：背景：先前已发现参与临床试验的吸入皮质类固醇（ICS）儿童的T2206C FCER2变体与IgE水平，恶化率和FCER2表达下降有关。此发现尚未复制。我们试图复制FCER2基因与哮喘患儿病情加重之间的关联。此外，我们测试了T2206C变体可能与类固醇抵抗性的其他标志物（例如哮喘症状评分和哮喘药物使用）相关的假设。方法：使用ICS的两个哮喘儿童群体的数据，探讨了T2206C变体对哮喘急性发作（急诊就诊或住院），症状评分和药物使用的影响：儿童哮喘药物的药理遗传学：具有抗炎作用的药物研究（n = 386）和呼吸研究（n = 939）。结果：在两个队列中，T2206C变异与哮喘相关医院就诊的风险增加相关（OR：1.91，95％CI：1.08-3.40），并且与先前发表的结果进行的荟萃分析具有高度意义（OR：2.38、95） ％CI：1.47-3.85，P ＝ 0.0004）。 FCER2变体还与通过哮喘控制问卷（OR：2.64，95％CI：1.00-6.98）测定的不受控制的哮喘风险增加相关，并且与每日类固醇剂量增加相关（OR：2.46，95％CI：1.38-4.39 ）。结论：在类固醇治疗的哮喘患者中，FCER2 T2206C变异体与哮喘相关住院之间的相关性似乎很强，并且可能与缺乏ICS疗效的其他指标（例如哮喘症状和每天需要更高剂量的ICS）相关。我们的结果表明，FCER2 T2206C变体可能是类固醇难治性患者的有用药理预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号